Clinical Trials
8 trialsNCT01638533 2025-02-07
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT04639843 2022-11-04
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT00062075 2015-12-04
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00079443 2013-07-01
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00114257 2013-02-11
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1 Completed
NCT00024180 2013-01-31
FR901228 in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00053963 2013-01-16
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00042822 2011-05-17
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed